that aspirin, as a well‐known salicylic acid‐based drug, can inhibit the activity of AKR1C1.[60] To verify the potential therapeutic effect of aspirin targeting AKR1C1 for BC, the minimum effective dose of aspirin (0.5 mm) was used to treat HCC1806 cells (Figure 6S). Here, AKR1C1 is linked to breast cancer.